vs
波士顿科学（BSX）与易贝（EBAY）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是易贝的1.8倍（$5.2B vs $3.0B），波士顿科学净利率更高（25.7% vs 17.8%，领先7.9%），易贝同比增速更快（15.0% vs 11.6%），过去两年波士顿科学的营收复合增速更高（12.4% vs 7.7%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
eBay是总部位于美国加利福尼亚州圣何塞的跨国电商企业，1995年9月由皮埃尔·奥米迪亚创立。其业务覆盖全球190个市场，旗下线上平台支持拍卖及“立即购买”两种销售模式，消费者可便捷选购各类商品，平台会在卖家完成交易后收取相应佣金。
BSX vs EBAY — 直观对比
营收规模更大
BSX
是对方的1.8倍
$3.0B
营收增速更快
EBAY
高出3.4%
11.6%
净利率更高
BSX
高出7.9%
17.8%
两年增速更快
BSX
近两年复合增速
7.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $3.0B |
| 净利润 | $1.3B | $528.0M |
| 毛利率 | 69.5% | 71.4% |
| 营业利润率 | — | 20.3% |
| 净利率 | 25.7% | 17.8% |
| 营收同比 | 11.6% | 15.0% |
| 净利润同比 | 99.0% | -22.2% |
| 每股收益（稀释后） | $0.90 | $1.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXEBAY
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $3.0B | ||
| Q3 25 | $5.1B | $2.8B | ||
| Q2 25 | $5.1B | $2.7B | ||
| Q1 25 | $4.7B | $2.6B | ||
| Q4 24 | $4.6B | $2.6B | ||
| Q3 24 | $4.2B | $2.6B | ||
| Q2 24 | $4.1B | $2.6B |
净利润BSXEBAY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $528.0M | ||
| Q3 25 | $755.0M | $632.0M | ||
| Q2 25 | $795.0M | $368.0M | ||
| Q1 25 | $672.0M | $503.0M | ||
| Q4 24 | $563.0M | $679.0M | ||
| Q3 24 | $468.0M | $634.0M | ||
| Q2 24 | $322.0M | $224.0M |
毛利率BSXEBAY
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 71.4% | ||
| Q3 25 | 69.9% | 70.9% | ||
| Q2 25 | 67.7% | 71.6% | ||
| Q1 25 | 68.8% | 72.0% | ||
| Q4 24 | 67.8% | 72.2% | ||
| Q3 24 | 68.8% | 71.8% | ||
| Q2 24 | 69.2% | 71.4% |
营业利润率BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 20.3% | ||
| Q3 25 | 20.7% | 20.4% | ||
| Q2 25 | 16.2% | 17.7% | ||
| Q1 25 | 19.8% | 23.8% | ||
| Q4 24 | 14.8% | 21.1% | ||
| Q3 24 | 17.4% | 23.1% | ||
| Q2 24 | 12.6% | 21.3% |
净利率BSXEBAY
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 17.8% | ||
| Q3 25 | 14.9% | 22.4% | ||
| Q2 25 | 15.7% | 13.5% | ||
| Q1 25 | 14.4% | 19.5% | ||
| Q4 24 | 12.3% | 26.3% | ||
| Q3 24 | 11.1% | 24.6% | ||
| Q2 24 | 7.8% | 8.7% |
每股收益（稀释后）BSXEBAY
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $1.14 | ||
| Q3 25 | $0.51 | $1.35 | ||
| Q2 25 | $0.53 | $0.79 | ||
| Q1 25 | $0.45 | $1.06 | ||
| Q4 24 | $0.38 | $1.35 | ||
| Q3 24 | $0.32 | $1.29 | ||
| Q2 24 | $0.22 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.9B |
| 总债务越低越好 | — | $6.0B |
| 股东权益账面价值 | — | $4.6B |
| 总资产 | — | $17.6B |
| 负债/权益比越低杠杆越低 | — | 1.30× |
8季度趋势，按日历期对齐
现金及短期投资BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $1.9B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $534.0M | $2.1B | ||
| Q1 25 | $725.0M | $3.1B | ||
| Q4 24 | $414.0M | $2.4B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.9B | $2.0B |
总债务BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $6.0B | ||
| Q3 25 | $11.1B | $5.0B | ||
| Q2 25 | $11.1B | $5.0B | ||
| Q1 25 | $10.5B | $5.8B | ||
| Q4 24 | $9.0B | $5.8B | ||
| Q3 24 | $9.2B | $6.2B | ||
| Q2 24 | $9.0B | $6.2B |
股东权益BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $4.6B | ||
| Q3 25 | $23.4B | $4.7B | ||
| Q2 25 | $22.4B | $4.7B | ||
| Q1 25 | $22.2B | $5.0B | ||
| Q4 24 | $21.8B | $5.2B | ||
| Q3 24 | $20.7B | $5.4B | ||
| Q2 24 | $20.4B | $5.5B |
总资产BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $17.6B | ||
| Q3 25 | $42.7B | $17.8B | ||
| Q2 25 | $41.6B | $18.0B | ||
| Q1 25 | $40.1B | $19.0B | ||
| Q4 24 | $39.4B | $19.4B | ||
| Q3 24 | $38.1B | $19.9B | ||
| Q2 24 | $37.1B | $20.4B |
负债/权益比BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 1.30× | ||
| Q3 25 | 0.48× | 1.06× | ||
| Q2 25 | 0.50× | 1.05× | ||
| Q1 25 | 0.47× | 1.16× | ||
| Q4 24 | 0.41× | 1.12× | ||
| Q3 24 | 0.45× | 1.14× | ||
| Q2 24 | 0.44× | 1.12× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $595.0M |
| 自由现金流经营现金流 - 资本支出 | — | $478.0M |
| 自由现金流率自由现金流/营收 | — | 16.1% |
| 资本支出强度资本支出/营收 | — | 3.9% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | — | $1.5B |
8季度趋势，按日历期对齐
经营现金流BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $595.0M | ||
| Q3 25 | $1.3B | $934.0M | ||
| Q2 25 | $1.3B | $-307.0M | ||
| Q1 25 | $541.0M | $787.0M | ||
| Q4 24 | $1.5B | $677.0M | ||
| Q3 24 | $1.0B | $755.0M | ||
| Q2 24 | $813.0M | $367.0M |
自由现金流BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $478.0M | ||
| Q3 25 | $1.2B | $803.0M | ||
| Q2 25 | $1.1B | $-441.0M | ||
| Q1 25 | $354.0M | $644.0M | ||
| Q4 24 | $1.2B | $560.0M | ||
| Q3 24 | $823.0M | $646.0M | ||
| Q2 24 | $658.0M | $278.0M |
自由现金流率BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 16.1% | ||
| Q3 25 | 22.9% | 28.5% | ||
| Q2 25 | 22.3% | -16.2% | ||
| Q1 25 | 7.6% | 24.9% | ||
| Q4 24 | 25.8% | 21.7% | ||
| Q3 24 | 19.6% | 25.1% | ||
| Q2 24 | 16.0% | 10.8% |
资本支出强度BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 3.9% | ||
| Q3 25 | 3.6% | 4.6% | ||
| Q2 25 | 3.1% | 4.9% | ||
| Q1 25 | 4.0% | 5.5% | ||
| Q4 24 | 6.1% | 4.5% | ||
| Q3 24 | 4.3% | 4.2% | ||
| Q2 24 | 3.8% | 3.5% |
现金转化率BSXEBAY
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 1.13× | ||
| Q3 25 | 1.78× | 1.48× | ||
| Q2 25 | 1.62× | -0.83× | ||
| Q1 25 | 0.81× | 1.56× | ||
| Q4 24 | 2.59× | 1.00× | ||
| Q3 24 | 2.14× | 1.19× | ||
| Q2 24 | 2.52× | 1.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
EBAY
| Marketplace Revenues | $2.4B | 82% |
| Advertising Revenues | $544.0M | 18% |
